This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cleerly, a digital healthcare company focused on heart disease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal CardiovascularImaging. Earls, MD , Chief Medical Officer of Cleerly.
Christian Tesche (Division of CardiovascularImaging, Department of Radiology and Radiological Science, Medical University of South Carolina and Department of Cardiology, Munich University Clinic, Ludwig-Maximilian-University).
Attendees can join with their peers and participate in sessions on structural heart disease, congenital heart disease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronaryarterydisease, vascular heart disease, debates and games and early career topics. for all attendees.
milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: CardiovascularImaging on March 13, 2024.
Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. Cleerly’s pioneering approach to advanced cardiovascularimaging, powered by AI-driven analysis, is elevating the field of diagnostic tools for coronaryarterydisease.
Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and discussed at the Radiological Society of North America109th Scientific Assembly and Annual Meeting (RSNA23). As a whole, the computed tomography market size in the US in 2024 is estimated to be $2.38
Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.
a leader in non-invasive artificial intelligence (AI) heart care solutions, announced that the data from its REVEALPLAQUE study , highlighting the accuracy of its Plaque Analysis, was published in the European Heart Journal CardiovascularImaging. 1 Heart disease is the leading cause of death for both men and women.²
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content